Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
114772-54-2N#Cc1ccccc1-c1ccc(CBr)cc1LFFIEVAMVPCZNA-UHFFFAOYSA-N114772-54-2DTXSID30363559Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H317 (97.6%): May cause an allergic skin reaction [Warning Sensitization, Skin]
P261, P272, P273, P280, P302+P352, P321, P333+P317, P362+P364, P391, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 42 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Warning
H302 (20%): Harmful if swallowed [Warning Acute toxicity, oral]
REACH registered substance: 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile (EC: 425-280-5)
REACH registered substance: (Bromomethylphenyl-4')-2 benzonitrile (EC: 601-327-7)
Skin Sens. 1 (97.6%)
Acute Tox. 4 (20%)
Beschreibung4-Bromomethyl-2-cyanobiphenyl is an important pharmaceutical intermediate and organic synthetic material used in the preparation of drugs of the sartan class such as azilsartan ester and temisartan. It is also used in the synthesis of other pyrazolines and related derivatives. In addition, recently reported studies on the role of 4-Bromomethyl-2-cyanobiphenyl in the determination of potential genotoxic impurities in temesartan using ESI-MS/MS technique and thermodynamic studies in different solvents[1-2].
Verwenden4-Bromomethyl-2-cyanobiphenyl used in protein-binding studies of quinoxaline angiotensin II receptor antagonists.